Granza Bio
ActiveBuilding programmable therapeutics for the immune system
About
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
Founders
Ashwin Nandakumar· FounderAshwin completed his PhD (DPhil) in Oncology at the University of Oxford. After completing his PhD, he began working as a Cancer Research UK post-doctoral researcher at Oxford University and also at the Institute of Cancer Research (ICR), London. He also brings experience setting up oncology clinical trials and working in oncology start-ups.
Ashwin Jainarayanan· FounderGranza Bio, DPhil (PhD) in Interdisciplinary Bioscience - University of Oxford
Product launches · 1 launch
- 🎯🦠 Granza Bio – Cancer targeting attack particles derived from our body’s immune system ↗▲ 762Feb 28, 2024
We engineer "attack particles" that selectively target and kill cancer cells, eliminating unwanted side effects and toxicity.
Change history · 10 recorded
- July 5, 2026
- Founder profile updated08:00 PM
- YC partner updated08:00 PM
- Launches refreshed08:00 PM
- July 1, 2026
- Pitch updated07:00 PM
- June 21, 2026
- Launches refreshed08:00 PM
- YC partner updated08:00 PM
- Founder profile updated08:00 PM
- June 7, 2026
- YC partner updated08:01 PM
- Launches refreshed08:01 PM
- Founder profile updated08:01 PM